scholarly journals Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry

2018 ◽  
Vol 5 (2) ◽  
pp. 537-550 ◽  
Author(s):  
Philip J. Mease ◽  
Désirée van der Heijde ◽  
Chitra Karki ◽  
Mei Liu ◽  
Yujin Park ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Observational Study ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
The Us ◽  
Factor Inhibitor ◽  
Necrosis Factor

scholarly journals Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis

PLoS ONE ◽  
2015 ◽  
Vol 10 (12) ◽  
pp. e0144655 ◽  
Author(s):  
Inês P. Perpétuo ◽  
Rita Raposeiro ◽  
Joana Caetano-Lopes ◽  
Elsa Vieira-Sousa ◽  
Raquel Campanilho-Marques ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Inhibitor Therapy ◽  
Factor Inhibitor ◽  
Necrosis Factor

scholarly journals Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis

PLoS ONE ◽  
2016 ◽  
Vol 11 (12) ◽  
pp. e0168958 ◽  
Author(s):  
Jun Won Park ◽  
Hyun Mi Kwon ◽  
Jin Kyun Park ◽  
Ja-Young Choi ◽  
Eun Bong Lee ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Radiographic Progression ◽  
Tumor Necrosis Factor Inhibitor ◽  
Factor Inhibitor ◽  
Necrosis Factor

scholarly journals Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis

2019 ◽  
Vol 47 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Jürgen Braun ◽  
Xenofon Baraliakos ◽  
Uta Kiltz ◽  
Klaus Krüger ◽  
Gerd R. Burmester ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Tumor Necrosis Factor ◽  
Disease Activity ◽  
Tumor Necrosis ◽  
Activity Index ◽  
Tumor Necrosis Factor Inhibitor ◽  
Disease Activity Index ◽  
Factor Inhibitor ◽  
Group 2 ◽  
Necrosis Factor

Objective.International recommendations for the management of axial spondyloarthritis including ankylosing spondylitis (AS) recommend a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) level of disease activity of ≥ 4 to initiate treatment with biologics. We aimed to evaluate the level of disease activity used to initiate tumor necrosis factor inhibitor (TNFi) treatment and the level of responses to treatment based on different BASDAI cutoffs.Methods.This is a posthoc analysis of the noninterventional, prospective, GO-NICE study in the subgroup of biologic-naive AS treated with golimumab (GOL) 50 mg subcutaneously once monthly.Results.Of the 244 biologic-naive AS patients at baseline, 70.5% had a BASDAI ≥ 4 (Group 1), 14.3% had 2.8 to < 4 (Group 2), and 15.2% had even < 2.8 (Group 3). A total of 134 patients (54.9%) completed the 24-month observational period. The mean BASDAI in Groups 1, 2, and 3 was initially 5.9 ± 1.3, 3.4 ± 0.4, and 2.0 ± 0.8, decreased to 2.2 ± 2.0, 1.9 ± 1.2, and 1.0 ± 1.2 within 3 months (all p < 0.0001 vs baseline), and decreased significantly to 2.2 ± 1.7, 1.9 ± 1.7, and 1.4 ± 1.0 at Month 24 (all p < 0.005), respectively. BASDAI 50% improvement was noted in 68.8%, 44.8%, and 45.2% of patients at Month 3, and in 84.9%, 61.9%, and 55.0% at Month 24.Conclusion.TNFi treatment was initiated in almost a third of AS patients with lower disease activity states as assessed by BASDAI cutoff of ≥ 4. Patients with a BASDAI between 2.8 and < 4 appeared to benefit significantly from GOL treatment, while patients with BASDAI < 2.8 did not. This finding should lead to a reevaluation of the established BASDAI cutoff of ≥ 4.

Sign in / Sign up

Export Citation Format

Share Document